VBCG
FLGT icon

Valley Brook Capital Group’s Fulgent Genetics FLGT Stock Holding History

Valley Brook Capital Group’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-535
Closed -$51K – 211
2021
Q1 		$51K Buy
535
+35
+7% +$3.61K 0.05% 216
2020
Q4 		$26K Buy
+500
New +$20.9K 0.03% 260

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Valley Brook Capital Group's FLGT Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 535 shares — an estimated $51K sold.

Valley Brook Capital Group first reported a position in FLGT in Q4 2020 and held it in 2 quarters. The position peaked at $51K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 535 Fulgent Genetics shares in Q2 2021, an estimated $51K.
  • Valley Brook Capital Group first reported a position in Fulgent Genetics in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Fulgent Genetics position peaked at $51K in Q1 2021.
  • 254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.